DK0616640T3 - Fremstilling af anti-selv antistoffer fra repertoirer af antistofsegmenter og fremvist på fag - Google Patents

Fremstilling af anti-selv antistoffer fra repertoirer af antistofsegmenter og fremvist på fag

Info

Publication number: DK0616640T3
Authority: DK; Denmark
Prior art keywords: repertoires; phage; presented; preparation; self antibodies
Prior art date: 1991-12-02

Application number

DK92924775T

Other languages

English (en)

Inventor

Andrew David Lilac C Griffiths

Geoffrey Walter Burns Ba Grigg

Gregory Paul Winter

Hendricus Renerus J Hoogenboom

James David Marks

John Mccafferty

Original Assignee

Medical Res Council

Cambridge Antibody Tech

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-12-02

Filing date

1992-12-02

Publication date

2004-12-20

1991-12-02 Priority claimed from GB919125582A external-priority patent/GB9125582D0/en

1991-12-02 Priority claimed from GB919125579A external-priority patent/GB9125579D0/en

1992-03-24 Priority claimed from GB929206372A external-priority patent/GB9206372D0/en

1992-03-24 Priority claimed from GB929206318A external-priority patent/GB9206318D0/en

1992-09-23 Priority claimed from PCT/GB1992/001755 external-priority patent/WO1993006213A1/en

1992-12-02 Application filed by Medical Res Council, Cambridge Antibody Tech filed Critical Medical Res Council

1992-12-02 Priority claimed from PCT/GB1992/002240 external-priority patent/WO1993011236A1/en

2004-12-20 Application granted granted Critical

2004-12-20 Publication of DK0616640T3 publication Critical patent/DK0616640T3/da

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3007—Carcino-embryonic Antigens
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
- C07K16/3092—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/34—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood group antigens
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
- C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00718—Type of compounds synthesised
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
- C07K2319/41—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a Myc-tag
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Life Sciences & Earth Sciences (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Genetics & Genomics (AREA)
Medicinal Chemistry (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Biochemistry (AREA)
General Health & Medical Sciences (AREA)
Cell Biology (AREA)
Hematology (AREA)
Oncology (AREA)
Endocrinology (AREA)
Virology (AREA)
Peptides Or Proteins (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

DK92924775T 1991-12-02 1992-12-02 Fremstilling af anti-selv antistoffer fra repertoirer af antistofsegmenter og fremvist på fag DK0616640T3 (da)

Applications Claiming Priority (6)

Application Number	Priority Date	Filing Date	Title
GB919125582A GB9125582D0 (en)	1991-12-02	1991-12-02	Binding molecules 2
GB919125579A GB9125579D0 (en)	1991-07-10	1991-12-02	Binding molecules 1
GB929206372A GB9206372D0 (en)	1992-03-24	1992-03-24	Binding substances
GB929206318A GB9206318D0 (en)	1992-03-24	1992-03-24	Binding substances
PCT/GB1992/001755 WO1993006213A1 (en)	1991-09-23	1992-09-23	Production of chimeric antibodies - a combinatorial approach
PCT/GB1992/002240 WO1993011236A1 (en)	1991-12-02	1992-12-02	Production of anti-self antibodies from antibody segment repertoires and displayed on phage

Publications (1)

Publication Number	Publication Date
DK0616640T3 true DK0616640T3 (da)	2004-12-20

Family

ID=27517085

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK92924775T DK0616640T3 (da)	1991-12-02	1992-12-02	Fremstilling af anti-selv antistoffer fra repertoirer af antistofsegmenter og fremvist på fag

Country Status (6)

Country	Link
EP (3)	EP2224006A1 (da)
JP (1)	JP3949712B2 (da)
AU (1)	AU665221B2 (da)
CA (1)	CA2124460C (da)
DE (1)	DE69233408T2 (da)
DK (1)	DK0616640T3 (da)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1993011236A1 (en)	1991-12-02	1993-06-10	Medical Research Council	Production of anti-self antibodies from antibody segment repertoires and displayed on phage
ES2176484T3 (es) *	1995-08-18	2002-12-01	Morphosys Ag	Bancos de proteinas/(poli)peptidos.
GB9722131D0 (en) *	1997-10-20	1997-12-17	Medical Res Council	Method
JP2001275682A (ja) *	2000-03-31	2001-10-09	Kankyo Meneki Gijutsu Kenkyusho:Kk	抗マラチオンモノクローナル抗体をコードする遺伝子
EP1433793A4 (en) *	2001-09-13	2006-01-25	Inst Antibodies Co Ltd	METHOD FOR CREATING A CAMEL ANTIBODY LIBRARY
NZ534107A (en)	2001-12-18	2007-02-23	Cancer Rec Tech Ltd	Creating and maintaining a cell line that produces a constitutively active signal transducer of activation and transcription (CA-STAT) protein
DE10346627A1 (de) *	2003-10-08	2005-05-19	Weiss, Stefan, PD Dr.	Single-chain-Antikörper gegen den 37 kDa/67 kDa Lamininrezeptor als Werkzeuge zur Diagnose und Therapie von Prionerkrankungen und Krebs, deren Herstellung und Verwendung
WO2005097832A2 (en)	2004-03-31	2005-10-20	Genentech, Inc.	Humanized anti-tgf-beta antibodies
GB0611116D0 (en)	2006-06-06	2006-07-19	Oxford Genome Sciences Uk Ltd	Proteins
EA200970250A1 (ru)	2006-09-05	2010-02-26	Медарекс, Инк.	Антитела к костным морфогенетическим белкам и их рецепторам и способы их применения
ME02269B (me)	2006-10-02	2016-04-28	Medarex Inc	Humana antitela koja se vezuju za cxcr4 i njihove upotrebe
KR20150067395A (ko)	2006-12-01	2015-06-17	메다렉스, 엘.엘.시.	씨디22에 결합하는 인간 항체 및 이의 용도
CL2007003622A1 (es)	2006-12-13	2009-08-07	Medarex Inc	Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales.
NZ578354A (en)	2006-12-14	2012-01-12	Medarex Inc	Antibody-partner molecule conjugates that bind cd70 and uses thereof
WO2008104803A2 (en)	2007-02-26	2008-09-04	Oxford Genome Sciences (Uk) Limited	Proteins
DK2447719T3 (da)	2007-02-26	2016-10-10	Oxford Biotherapeutics Ltd	Proteiner
EP2242771B1 (en)	2007-12-14	2013-07-17	Bristol-Myers Squibb Company	Binding molecules to the human ox40 receptor
CN102177438A (zh)	2008-07-25	2011-09-07	理查德·W·瓦格纳	蛋白筛选方法
WO2010084408A2 (en)	2009-01-21	2010-07-29	Oxford Biotherapeutics Ltd.	Pta089 protein
UA102891C2 (uk)	2009-03-05	2013-08-27	Медарекс, Інк.	Повні людські антитіла, специфічні до cadm1
MA33276B1 (fr)	2009-04-20	2012-05-02	Oxford Biotherapeutics Ltd	Anticorps spécifiques à la cadhérine-17
ES2545792T5 (es)	2009-05-20	2018-09-14	Novimmune Sa	Bancos de polipéptidos sintéticos y métodos para generar variantes de polipéptidos diversificados de forma natural
EP2470569A1 (en)	2009-10-13	2012-07-04	Oxford Biotherapeutics Ltd.	Antibodies against epha10
WO2011054007A1 (en)	2009-11-02	2011-05-05	Oxford Biotherapeutics Ltd.	Ror1 as therapeutic and diagnostic target
WO2011054893A2 (en)	2009-11-05	2011-05-12	Novartis Ag	Biomarkers predictive of progression of fibrosis
AU2011214465A1 (en)	2010-02-10	2012-08-30	Novartis Ag	Methods and compounds for muscle growth
WO2011138392A1 (en)	2010-05-06	2011-11-10	Novartis Ag	Compositions and methods of use for therapeutic low density lipoprotein -related protein 6 (lrp6) antibodies
PE20130206A1 (es)	2010-05-06	2013-02-28	Novartis Ag	Anticuerpos multivalentes antagonistas de lrp6 (proteina relacionada con lipoproteinas de baja densidad 6) y composiciones
ME02637B (me)	2010-08-20	2017-06-20	Novartis Ag	Antitela za receptor 3 faktora rasta epiderma (her3)
CA2810359C (en)	2010-09-09	2021-06-22	Pfizer Inc.	4-1bb binding molecules
PT2726094T (pt)	2011-06-28	2017-02-10	Oxford Biotherapeutics Ltd	Alvo terapêutico e de diagnóstico
ES2640960T3 (es)	2011-06-28	2017-11-07	Oxford Biotherapeutics Ltd.	Anticuerpos para ADP-ribosil ciclasa 2
US8883735B2 (en)	2011-11-04	2014-11-11	Novartis Ag	Low density lipoprotein-related protein 6 (LRP6)-half life extender constructs
KR20140103135A (ko)	2011-12-05	2014-08-25	노파르티스 아게	Her3의 도메인 ii에 대해 지시된 표피 성장 인자 수용체 3 (her3)에 대한 항체
ES2758433T3 (es)	2011-12-05	2020-05-05	Novartis Ag	Anticuerpos contra el receptor 3 del factor de crecimiento epidérmico (HER3)
US9475872B2 (en)	2011-12-28	2016-10-25	Immunoqure Ag	Nucleic acid molecules encoding moonoclonal antibodies speceific for IL17F
US10112988B2 (en)	2012-01-09	2018-10-30	Icb International, Inc.	Methods of assessing amyloid-beta peptides in the central nervous system by blood-brain barrier permeable peptide compositions comprising a vab domain of a camelid single domain heavy chain antibody against an anti-amyloid-beta peptide
US10112987B2 (en)	2012-01-09	2018-10-30	Icb International, Inc.	Blood-brain barrier permeable peptide compositions comprising a vab domain of a camelid single domain heavy chain antibody against an amyloid-beta peptide
SG11201408330XA (en)	2012-05-24	2015-01-29	Mountgate Group Ltd	Compositions and methods related to prevention and treatment of rabies infection
GB201213652D0 (en)	2012-08-01	2012-09-12	Oxford Biotherapeutics Ltd	Therapeutic and diagnostic target
GB201302447D0 (en)	2013-02-12	2013-03-27	Oxford Biotherapeutics Ltd	Therapeutic and diagnostic target
AU2014223824B2 (en)	2013-02-28	2020-02-27	Albert Einstein College Of Medicine, Inc.	Tuberculosis biomarkers and uses thereof
CN105246916A (zh)	2013-03-14	2016-01-13	诺华股份有限公司	针对notch 3的抗体
KR102402973B1 (ko)	2013-07-03	2022-05-27	이뮤노큐어 아게	인간 항-ifn-알파 항체
SG11201600171SA (en)	2013-08-02	2016-02-26	Pfizer	Anti-cxcr4 antibodies and antibody-drug conjugates
CN107663240B (zh) *	2016-07-29	2021-01-12	中国人民解放军第四军医大学	高度糖基化cea特异性结合的单链抗体及其在检测和治疗上的应用
ES3041722T3 (en)	2016-07-29	2025-11-14	Inst Nat Sante Rech Med	Antibodies targeting tumor associated macrophages and uses thereof
CN110392697A (zh)	2017-03-02	2019-10-29	国家医疗保健研究所	对nectin-4具有特异性的抗体及其用途
US11174322B2 (en)	2017-07-24	2021-11-16	INSERM (Institut National de la Santé et de la Recherche Médicale)	Antibodies and peptides to treat HCMV related diseases
WO2019036855A1 (en)	2017-08-21	2019-02-28	Adagene Inc.	Anti-cd137 molecules and use thereof
WO2019094595A2 (en)	2017-11-09	2019-05-16	Pinteon Therapeutics Inc.	Methods and compositions for the generation and use of humanized conformation-specific phosphorylated tau antibodies
WO2019139987A1 (en)	2018-01-09	2019-07-18	Elstar Therapeutics, Inc.	Calreticulin binding constructs and engineered t cells for the treatment of diseases
WO2019148444A1 (en)	2018-02-02	2019-08-08	Adagene Inc.	Anti-ctla4 antibodies and methods of making and using the same
WO2019148445A1 (en)	2018-02-02	2019-08-08	Adagene Inc.	Precision/context-dependent activatable antibodies, and methods of making and using the same
US12152073B2 (en)	2018-03-14	2024-11-26	Marengo Therapeutics, Inc.	Multifunctional molecules that bind to calreticulin and uses thereof
WO2019244107A1 (en)	2018-06-21	2019-12-26	Daiichi Sankyo Company, Limited	Compositions including cd3 antigen binding fragments and uses thereof
CN112955465A (zh)	2018-07-03	2021-06-11	马伦戈治疗公司	抗tcr抗体分子及其用途
US20220047701A1 (en)	2018-09-10	2022-02-17	INSERM (Institut National de la Santé et de la Recherche Médicale)	Combination of her2/neu antibody with heme for treating cancer
CN119661722A (zh)	2019-02-21	2025-03-21	马伦戈治疗公司	结合t细胞相关癌细胞的多功能分子及其用途
CN119039441A (zh)	2019-02-21	2024-11-29	马伦戈治疗公司	与nkp30结合的抗体分子及其用途
EP3938400B1 (en)	2019-03-11	2025-07-30	Memorial Sloan Kettering Cancer Center	Cd22 antibodies and methods of using the same
WO2020193520A1 (en)	2019-03-25	2020-10-01	INSERM (Institut National de la Santé et de la Recherche Médicale)	Treatment of taupathy disorders by targeting new tau species
WO2021058729A1 (en)	2019-09-27	2021-04-01	INSERM (Institut National de la Santé et de la Recherche Médicale)	Anti-müllerian inhibiting substance type i receptor antibodies and uses thereof
WO2021058763A1 (en)	2019-09-27	2021-04-01	INSERM (Institut National de la Santé et de la Recherche Médicale)	Anti-müllerian inhibiting substance antibodies and uses thereof
EP4072682A1 (en)	2019-12-09	2022-10-19	Institut National de la Santé et de la Recherche Médicale (INSERM)	Antibodies having specificity to her4 and uses thereof
GB2609554B (en)	2020-01-03	2025-08-20	Marengo Therapeutics Inc	Anti-TCR antibody molecules and uses thereof
JP2023525053A (ja)	2020-05-12	2023-06-14	インサーム（インスティテュナシオナルドゥラサンテエドゥラルシェルシェメディカル）	皮膚ｔ細胞リンパ腫及びｔｆｈ由来リンパ腫を処置する新しい方法
JP2023525085A (ja)	2020-05-13	2023-06-14	アダジーンアーゲー	がんを治療するための組成物および方法
EP4277664A1 (en)	2021-01-13	2023-11-22	Memorial Sloan Kettering Cancer Center	Antibody-pyrrolobenzodiazepine derivative conjugate
CN117425500A (zh)	2021-01-13	2024-01-19	纪念斯隆凯特琳癌症中心	抗dll3抗体-药物缀合物
KR20240004462A (ko)	2021-04-08	2024-01-11	마렝고 테라퓨틱스, 인크.	Tcr에 결합하는 다기능성 분자 및 이의 용도
WO2023175171A1 (en)	2022-03-18	2023-09-21	Inserm (Institut National De La Sante Et De La Recherche Medicale)	Bk polyomavirus antibodies and uses thereof
WO2024052503A1 (en)	2022-09-08	2024-03-14	Institut National de la Santé et de la Recherche Médicale	Antibodies having specificity to ltbp2 and uses thereof
WO2024056668A1 (en)	2022-09-12	2024-03-21	Institut National de la Santé et de la Recherche Médicale	New anti-itgb8 antibodies and its uses thereof
WO2025012417A1 (en)	2023-07-13	2025-01-16	Institut National de la Santé et de la Recherche Médicale	Anti-neurotensin long fragment and anti-neuromedin n long fragment antibodies and uses thereof
WO2025032158A1 (en)	2023-08-08	2025-02-13	Institut National de la Santé et de la Recherche Médicale	Method to treat tauopathies
WO2025073890A1 (en)	2023-10-06	2025-04-10	Institut National de la Santé et de la Recherche Médicale	Method to capture circulating tumor extracellular vesicles
WO2025114411A1 (en)	2023-11-29	2025-06-05	Institut National de la Santé et de la Recherche Médicale	New method to treat brain or neurologic disorders
WO2025224297A1 (en)	2024-04-26	2025-10-30	Institut National de la Santé et de la Recherche Médicale	Antibodies having specificity to tgfbi and uses thereof
WO2025242732A1 (en)	2024-05-21	2025-11-27	Institut National de la Santé et de la Recherche Médicale	Pan antibodies against sars-cov-2 spike protein and uses thereof for therapeutical purposes
WO2025242910A1 (en)	2024-05-23	2025-11-27	Egle Therapeutics	Il18r agonist antibodies and uses thereof
EP4653460A1 (en)	2024-05-23	2025-11-26	Egle Therapeutics	Il18r agonist antibodies and uses thereof
WO2025248097A2 (en)	2024-05-31	2025-12-04	Gamamabs Pharma	Humanized anti-human her3 antibodies and uses thereof
WO2025257181A1 (en)	2024-06-11	2025-12-18	Institut National de la Santé et de la Recherche Médicale	Antibodies targeting trans-active response dna-binding protein-43 (tdp-43)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE114723T1 (de) *	1987-03-02	1994-12-15	Enzon Lab Inc	Organismus als träger für ''single chain antibody domain (scad)''.
WO1990005144A1 (en) *	1988-11-11	1990-05-17	Medical Research Council	Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
CA2057923A1 (en) *	1989-05-16	1990-11-17	William D. Huse	Co-expression of heteromeric receptors
CA2016842A1 (en) *	1989-05-16	1990-11-16	Richard A. Lerner	Method for tapping the immunological repertoire
CA2016841C (en) *	1989-05-16	1999-09-21	William D. Huse	A method for producing polymers having a preselected activity
ES2139598T3 (es) *	1990-07-10	2000-02-16	Medical Res Council	Procedimientos para la produccion de miembros de parejas de union especifica.
GB9015198D0 (en) *	1990-07-10	1990-08-29	Brien Caroline J O	Binding substance

1992
- 1992-12-02 AU AU30890/92A patent/AU665221B2/en not_active Expired
- 1992-12-02 EP EP10002988A patent/EP2224006A1/en not_active Withdrawn
- 1992-12-02 DK DK92924775T patent/DK0616640T3/da active
- 1992-12-02 CA CA002124460A patent/CA2124460C/en not_active Expired - Lifetime
- 1992-12-02 JP JP50996793A patent/JP3949712B2/ja not_active Expired - Lifetime
- 1992-12-02 DE DE69233408T patent/DE69233408T2/de not_active Expired - Lifetime
- 1992-12-02 EP EP92924775A patent/EP0616640B1/en not_active Expired - Lifetime
- 1992-12-02 EP EP00107845A patent/EP1024191B8/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
JPH07502167A (ja)	1995-03-09
AU665221B2 (en)	1995-12-21
CA2124460A1 (en)	1993-06-10
EP2224006A1 (en)	2010-09-01
EP0616640B1 (en)	2004-09-01
EP1024191B1 (en)	2008-09-10
EP0616640A1 (en)	1994-09-28
JP3949712B2 (ja)	2007-07-25
EP1024191A2 (en)	2000-08-02
AU3089092A (en)	1993-06-28
DE69233408D1 (de)	2004-10-07
DE69233408T2 (de)	2005-09-22
CA2124460C (en)	2007-08-28
EP1024191B8 (en)	2008-11-05
EP1024191A3 (en)	2004-03-31

Publication	Publication Date	Title
DK0616640T3 (da)	2004-12-20	Fremstilling af anti-selv antistoffer fra repertoirer af antistofsegmenter og fremvist på fag
ATE144624T1 (de)	1996-11-15	Neue antikörper und verfahren zu ihrer verwendung
FI962377A0 (fi)	1996-06-07	Humanisoituja vasta-aineita ja niiden käyttö
FI941572A7 (fi)	1994-05-27	Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä
DK0531539T3 (da)	1998-10-12	Frysetørret præparation af monoklonale antistoffer
FI981765L (fi)	1998-08-17	Sytokiinin vastainen vasta-aine ja menetelmä sen valmistamiseksi
GB2250995B (en)	1994-05-18	Multivalent antigen-binding proteins
FI930580L (fi)	1993-04-02	Tri- och tetravalensiska monopecifika antigen bindande proteiner
NO964583D0 (no)	1996-10-29	Lettvekts brönnsementsammensetninger og fremgangsmåter
DK0941121T3 (da)	2005-01-31	Stabile lyofiliserede farmaceutiske præparater af mono- eller polyklonale antistoffer
DE69622663D1 (de)	2002-09-05	Zweistufige vorausholungspufferstruktur und verfahren mit bypass
NO986050D0 (no)	1998-12-22	Renset overflate antigen monoklonalt antistoff fra spermier og anvendelse d
DE69232670D1 (de)	2002-08-08	Tropfendetektor und Verfahren
DE69128114D1 (de)	1997-12-11	Bildgerät und Verfahren
DE69126933D1 (de)	1997-08-28	Abbildungsgerät und Verfahren
IS4013A (is)	1993-11-07	Sjálfvirk botnvarpa og notkunaraðferð
DE69129729D1 (de)	1998-08-13	FIFO-Puffer
DE69122906D1 (de)	1996-12-05	FIFO-Puffer
DK136591D0 (da)	1991-07-16	Katalysatorer indeholdende polyvalent metalion og et antistof-kombinerende sted
NO915017L (no)	1992-12-28	Monoklonale antistoffer og fremgangsmaate for deres fremstilling
DE69321986D1 (de)	1998-12-17	Probenröhrchenbehälter und magnetische Förderanlage
DE69131542D1 (de)	1999-09-30	Bildkodierungsgerät und Verfahren
DK1696031T3 (da)	2010-08-02	Fremstilling af anti-autoantigener fra antistofsegmentrepertoirer og præsentere på fag
FI943524A7 (fi)	1994-07-27	Hepatiitti C -viruksen vastaisia monoklonaalisia vasta-aineita ja anti -idiotyyppisiä vasta-aineita
MX9202642A (es)	1992-12-01	Anticuerpos monoclonales y antigeno para melanoma humano.